Pages that link to "Q69520763"
Jump to navigation
Jump to search
The following pages link to Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody (Q69520763):
Displaying 50 items.
- Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical (Q24681992) (← links)
- Tetraspanins as therapeutic targets in hematological malignancy: a concise review (Q27002353) (← links)
- AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML (Q30403563) (← links)
- Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides (Q33645793) (← links)
- Monoclonal antibody therapy for B cell non-Hodgkin's lymphomas: emerging concepts of a tumour-targeted strategy (Q33735451) (← links)
- Clinical radioimmunotherapy (Q33869330) (← links)
- 177Lu-DOTA-HH1, a novel anti-CD37 radio-immunoconjugate: a study of toxicity in nude mice. (Q33961370) (← links)
- Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants. (Q34029619) (← links)
- Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. (Q34122286) (← links)
- Effect of an anti-human Co-029/tspan8 mouse monoclonal antibody on tumor growth in a nude mouse model (Q34211752) (← links)
- Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing (Q34288940) (← links)
- Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma (Q34318792) (← links)
- Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma (Q34480345) (← links)
- Choosing an optimal radioimmunotherapy dose for clinical response (Q34551589) (← links)
- Cancer Radioimmunotherapy (Q35070045) (← links)
- Radioimmunotherapy for non-Hodgkin's lymphoma (Q35206373) (← links)
- A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies (Q35483665) (← links)
- Principles of antibody therapy (Q35660057) (← links)
- 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. (Q35849468) (← links)
- Radioimmunotherapy of non-Hodgkin's lymphoma: clinical development of the Zevalin regimen (Q35927598) (← links)
- Does immunoscintigraphy serve clinical needs effectively? Is there a future for radioimmunotherapy? (Q36050826) (← links)
- Targeting of tetraspanin proteins--potential benefits and strategies (Q36533706) (← links)
- Biologic Agents and Approaches in the Management of Patients with Lymphoma: A Critical Appraisal (Q36692582) (← links)
- New approaches to the treatment of follicular lymphoma (Q36704163) (← links)
- Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies (Q36832137) (← links)
- Clinical applications of fusion imaging in oncology (Q36874007) (← links)
- Controversies in the management of non-Hodgkin lymphoma (Q37084120) (← links)
- A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. (Q37169112) (← links)
- Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates (Q37295150) (← links)
- Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies (Q37364355) (← links)
- A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia (Q37609420) (← links)
- Imaging in targeted delivery of therapy to cancer (Q37617137) (← links)
- Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy (Q37720857) (← links)
- Chemotherapy of non-Hodgkin's lymphomas (Q37732513) (← links)
- Radioactive Antibodies: A Historical Review of Selective Targeting and Treatment of Cancer (Q37796519) (← links)
- Clinical radioimmunotherapy--the role of radiobiology. (Q37953785) (← links)
- Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody (Q38532869) (← links)
- Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma (Q38550992) (← links)
- Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies (Q38795442) (← links)
- Novel Insights into Membrane Targeting of B Cell Lymphoma. (Q39441297) (← links)
- The Management of Follicular Lymphoma (Q40394277) (← links)
- Myeloablative Radiolabeled Antibody Therapy with Autologous Bone marrow Transplantation for Relapsed B Cell Lymphomas (Q40424134) (← links)
- Radio-immunotherapy dosimetry with special emphasis on SPECT quantification and extracorporeal immuno-adsorption (Q40585371) (← links)
- Recent developments in radioimmunotherapy (Q40602865) (← links)
- Radioimmunotherapy of the Non-Hodgkin's Lymphomas (Q40969254) (← links)
- A pharmacokinetic model describing the removal of circulating radiolabeled antibody by extracorporeal immunoadsorption (Q41145178) (← links)
- Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2 (Q41525514) (← links)
- Preclinical investigation of the antitumour effects of anti-CD19-idarubicin immunoconjugates (Q41540554) (← links)
- Gallium-67 radiotoxicity in human U937 lymphoma cells (Q41561684) (← links)
- Intracellular catabolism of radiolabeled anti-CD3 antibodies by leukemic T cells (Q41662811) (← links)